HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Management of symptoms in step-down therapy of gastroesophageal reflux disease.

AbstractOBJECTIVE:
Majority of studies on gastroesophageal reflux disease (GERD) that include patients with or without erosive disease have documented the efficacy of proton pump inhibitors (PPIs) as well as their superiority to H(2)-receptor antagonist (H(2)-RA). The purpose of this study was to clarify the difference in quality of GERD treatment with PPIs and H(2)-RA in step-down protocol using lansoprazole.
METHODS:
Forty-three patients with reflux esophagitis were randomly divided into three groups and assessed by severity score; group 1 received 30 mg lansoprazole initially and maintenance therapy with a standard dose H(2)-RA; group 2 received 30 mg of lansoprazole initially and maintenance therapy of 15 mg lansoprazole; and group 3 received 15 mg of lansoprazole once daily for 16 weeks. If the patients experienced symptomatic recurrence while on H(2)-RA, they were switched to PPI maintenance.
RESULTS:
Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment. After 8 weeks, however, heartburn and regurgitation recurred at 50% and 78.6%, respectively, in the stepped down to famotidine group, and quality of life (QOL) was significantly impaired. Endoscopic ultrasonography (EUS) analysis showed reduction of the submucosal layer without any change in the mucosal surface in the stepped down to famotidine group.
CONCLUSIONS:
Step-down lansoprazole therapy is considered very effective in terms of rapid effect, long-term effect and high quality GERD treatment.
AuthorsShinichiro Mine, Takeshi Iida, Takahiro Tabata, Hirofumi Kishikawa, Yoshiya Tanaka
JournalJournal of gastroenterology and hepatology (J Gastroenterol Hepatol) Vol. 20 Issue 9 Pg. 1365-70 (Sep 2005) ISSN: 0815-9319 [Print] Australia
PMID16105122 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
CopyrightCopyright 2005 Blackwell Publishing Asia Pty Ltd.
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Enzyme Inhibitors
  • Histamine H2 Antagonists
  • Proton Pump Inhibitors
  • Lansoprazole
  • Famotidine
  • Omeprazole
Topics
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Aged
  • Deglutition Disorders (drug therapy)
  • Endosonography
  • Enzyme Inhibitors (therapeutic use)
  • Esophagitis, Peptic (drug therapy, etiology, ultrasonography)
  • Famotidine (therapeutic use)
  • Female
  • Gastroesophageal Reflux (complications, drug therapy, ultrasonography)
  • Heartburn (drug therapy)
  • Histamine H2 Antagonists (therapeutic use)
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole (analogs & derivatives, therapeutic use)
  • Proton Pump Inhibitors
  • Quality of Life
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: